DDX60 and cancer: Previous studies showed that treatment with RIG-I agonist resulted in the activation of proinflammatory transcription factors STAT1 and NF-κB and increased expression of MHC-I components in cancer cells [52,53], Therefore, DDX60 may serve as a signaling transductor to activate the RIG-I pathway.